Effects of a Single Bout of Exercise on Transcriptomics and Metabolomics in Adipose Tissue

February 21, 2025 updated by: Joslin Diabetes Center
The purpose of this study is to determine the effects of a single bout of exercise on changes in the genes and small molecules in blood and fat tissue, before and after a bout of exercise. This research may contribute to a better understanding of the beneficial effects of exercise on the body.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The national and international prevalence of both obesity and type 2 diabetes has risen dramatically over the last few decades, increasing the need for new therapies to treat these conditions. An established treatment for type 2 diabetes and obesity are regular physical activity and exercise. It has been shown that one single session of exercise can lead to adaptations in the blood and in tissues that improve systemic homeostasis overtime; while acute changes in skeletal muscle also play a critical role in these effects, changes in the adipose tissue and in the peripheral mononuclear cells (PBMCs) that may also contribute to this improvement. However, the beneficial effects of exercise on metabolism through these other tissues have not been intensively investigated.

The investigators hypothesize that a single session of exercise will result in changes to white adipose tissue, including changes in metabolites and gene expression, as well as changes in PBMCs, and that these adaptations may play an important role to improve metabolic homeostasis.

This hypothesis stems from the investigator's animal-based studies, which have led to the exciting discoveries that 1) exercise training-induced adaptations to subcutaneous white adipose tissue (scWAT) result in significant improvements in whole-body glucose tolerance and insulin sensitivity (1), and 2) the mechanism for this effect may be due to auto-, para-, or endocrine effects of novel exercise-induced circulating factors coming from adipose tissue. Thus, being able to further understand, and potentially mimick, these exercise-induced changes to scWAT could lead to novel therapies for obesity and type 2 diabetes.

Given the great interest in exercise mimetics as treatments for diabetes and obesity, it is essential to determine if a single session of exercise alters metabolites as well as gene expression in the scWAT in human subjects with obesity. To determine if a single session of exercise leads to changes in PBMCs, PBMC transcriptomics will be analyzed. This analysis will determine how exercise affects the number of specific cell types in the blood that can regulate metabolic health.

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Joslin Diabetes Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 20-60 years
  • Body mass index (BMI) ≥30.0 ± 0.1 and ≤40.0 ± 0.1 kg/m2
  • HbA1c ≤ 5.7 ± 0.1%
  • No history of diabetes (type 1 and type 2)
  • In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations
  • Willing to adhere to the protocol requirements for the duration of the study

Exclusion Criteria:

  • Exercises frequently i.e. ≥ 150 minutes per week of moderate intensity or ≥ 75 min high intensity.
  • Blood glucose rises ≥140mg/dl at 2 hours after OGTT on Visit 1
  • Use of weight loss medications (i.e. GLP-1 agonists)
  • Use of any medications related to diabetes
  • Use of beta-blockers
  • Use of anticoagulation and aspirin
  • Use of agents that affect hepatic glucose production such as beta adrenergic agonists, xanthine derivatives
  • Currently pregnant or breastfeeding
  • Current smoker
  • Heart or lung disease
  • Acute infection, including COVID-19 (current or recent infection of COVID-19 in the previous 3 months)
  • Any hospitalization due to COVID-19.
  • Severe hypertension (systolic >160 mmHg or diastolic >90 mmHg)
  • Inability to exercise for any reason
  • Any known contraindication to exercise testing based on current ACSM guidelines (5)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acute Bout of Exercise
Exercising for 60 minutes at 55-60% of VO₂ peak
Exercising for 60 minutes at 55-60% of VO₂ peak
No Intervention: No Exercise
No Exercise Session

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Transcriptome in white adipose tissue
Time Frame: Baseline; 2 hours
Gene transcription changes in RNA-based expression within subcutaneous adipose tissue
Baseline; 2 hours
Metabolome in fat
Time Frame: Baseline; 2 hours
Changes in concentration of metabolites within subcutaneous adipose tissue
Baseline; 2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Transcriptomic changes in peripheral blood mononuclear cell in people with obesity
Time Frame: Baseline; 2 hours
Gene transcription changes in RNA-based expression within peripheral blood mononuclear cells
Baseline; 2 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Roeland JW Middelbeek, MD, Joslin Diabetes Center
  • Principal Investigator: Laurie Goodyear, PhD, Joslin Diabetes Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 27, 2021

Primary Completion (Actual)

May 23, 2024

Study Completion (Actual)

May 23, 2024

Study Registration Dates

First Submitted

April 13, 2021

First Submitted That Met QC Criteria

April 28, 2021

First Posted (Actual)

April 29, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 21, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Acute Bout of Exercise

Subscribe